CCRAS calls for stronger evidence and safety monitoring to unlock Ayurveda market adoption

India’s Ayurvedic medicines and wellness category may face higher expectations on scientific validation, adverse-event reporting and pharmacovigilance. CCRAS says stronger safety systems are needed to build consumer trust, credibility and broader market adoption.

— Source publishedSun, 20 Sept, 2026, 16:19 IST·First seen Sun, 20 Sept, 2026, 16:29 IST·Source ET Small Business

What happened

CCRAS called for stronger scientific validation, adverse-event reporting and pharmacovigilance for Ayurvedic medicines and therapies, aiming to improve safety, credibility and market adoption in India’s growing Ayurveda and wellness category.

Key facts

  • Two-day symposium
  • 1996

Why this matters

Acquirers should prioritize targets with validated formulations, documented safety systems and regulatory capabilities as these assets become more important to category adoption.

What to watch

  • CCRAS, AYUSH or CDSCO issuance of formal pharmacovigilance, labeling, clinical-evidence or advertising guidelines.
  • Mandatory adverse-event reporting requirements or a centralized Ayurveda safety-reporting database.
  • Marketplace and quick-commerce policy changes requiring test certificates, claim substantiation or compliance documentation.
  • Rising product recalls, safety controversies or consumer litigation involving Ayurvedic formulations.
  • Major brands publishing clinical trials, safety dashboards or third-party certification programs.
  • Modern retail chains creating science-backed Ayurveda assortments or excluding unverified products.
  • Audit Ayurveda SKUs for substantiation, contraindication language, dosage instructions and adverse-event escalation processes.
  • Create a tiered claims framework separating traditional-use claims from clinically validated efficacy claims.
  • Prioritize suppliers with GMP compliance, batch traceability, standardized extracts and documented safety monitoring.
  • Build retailer-facing evidence packs for high-volume products and restrict unsupported digital marketing claims.
  • Monitor acquisition or partnership opportunities among testing labs, clinical-research providers and credible regional Ayurveda brands.